Unlocking the molecular and cellular mechanisms regulated by the ribonuclease Dis3L2 in Drosophila and human cell proliferation.
Lead Research Organisation:
University of Sussex
Department Name: Brighton and Sussex Medical School
Abstract
Development of a single egg cell into a complex multicellular organism requires exquisite control of cell proliferation. Regulation of cell proliferation is not only important during development but also required in regeneration and repair of damaged tissues and also during wound healing. Co-ordination of tissue growth is also crucial to maintain the correct size and shape of different organs. Similarly, controlled proliferation is important in evolution where growth of certain areas of the body (e.g the brain) may be favoured by natural selection. However, uncontrolled cell proliferation is a hallmark of cancer with many genes involved in growth and proliferation implicated in cancer progression. Although the pathways involved in uncontrolled cell proliferation as occurs in cancer are well known, the pathways governing normal, co-ordinated cell proliferation have not been as well studied.
Using human kidney cells as well as the fruit fly Drosophila we have recently discovered that cell proliferation can be regulated by a protein named Dis3L2. Depletion or removal of this protein results in excess proliferation. These results are relevant to human disease as DIS3L2 has been shown to be mutated in an overgrowth syndrome (Perlman syndrome) where affected children are larger than normal, have abnormal enlargement of organs (e.g. kidneys) and susceptibility to Wilms' tumour (a kidney cancer). In addition, up to 30% of sporadic Wilms' tumours have mutations in Dis3L2. Interestingly, Dis3L2 has also been implicated in body weight and height variation in indigenous Ethiopian sheep, suggesting selection in our domestic animals. Therefore, understanding the molecular mechanisms whereby Dis3L2 exerts its effects on tissue growth is likely to be relevant in normal growth as well as human overgrowth diseases.
Dis3L2 is an enzyme known to "chew up" and destroy mRNA molecules which instruct the cell to make particular proteins. This enzyme is remarkable in that it has a similar structure and function in a wide range of organisms, from bacteria through to humans. Using state-of-the-art molecular methods in fruit flies, we have discovered that Dis3L2 targets a small subset of mRNAs, including an mRNA encoding a growth factor named 'imaginal disc growth factor 2' (idgf2). Idgf2 has been previously shown to cause proliferation of fruit fly cells via an unknown pathway. For human kidney cells in culture, we have discovered that depletion of DIS3L2 results in enhanced proliferation, and that this involves a well known cellular pathway. We do not yet know the mRNA targets of DIS3L2 which activate this proliferation pathway in humans. These results are novel in that no other research group as yet has unravelled the cellular mechanisms linking DIS3L2 with cell proliferation.
The specific aims of this project are to understand the pathways and cellular mechanisms whereby Dis3L2 controls cell proliferation in Drosophila and in human kidney cells. We will use modern molecular and cell biological methods (such as CRISPR-Cas9 for gene editing) to dissect this proliferation pathway and identify key components. In fruit flies, we think that Dis3L2 directly targets idgf2 after it has been "tagged" for degradation by other cellular factors. We predict that Idgf2 then activates a specific cellular enhance cell proliferation. In humans, we predict that DIS3L2 targets another growth factor which in turn activates the same pathway to promote proliferation. We have the expertise, as well as the molecular and genetic tools to test these ideas. The knowledge gained during this project may facilitate treatments for cancer as well as help us to understand the ways that normal tissues grow and develop. This project will therefore provide valuable insights into a new way of regulating cell proliferation which can be used in the development of new therapeutics.
Using human kidney cells as well as the fruit fly Drosophila we have recently discovered that cell proliferation can be regulated by a protein named Dis3L2. Depletion or removal of this protein results in excess proliferation. These results are relevant to human disease as DIS3L2 has been shown to be mutated in an overgrowth syndrome (Perlman syndrome) where affected children are larger than normal, have abnormal enlargement of organs (e.g. kidneys) and susceptibility to Wilms' tumour (a kidney cancer). In addition, up to 30% of sporadic Wilms' tumours have mutations in Dis3L2. Interestingly, Dis3L2 has also been implicated in body weight and height variation in indigenous Ethiopian sheep, suggesting selection in our domestic animals. Therefore, understanding the molecular mechanisms whereby Dis3L2 exerts its effects on tissue growth is likely to be relevant in normal growth as well as human overgrowth diseases.
Dis3L2 is an enzyme known to "chew up" and destroy mRNA molecules which instruct the cell to make particular proteins. This enzyme is remarkable in that it has a similar structure and function in a wide range of organisms, from bacteria through to humans. Using state-of-the-art molecular methods in fruit flies, we have discovered that Dis3L2 targets a small subset of mRNAs, including an mRNA encoding a growth factor named 'imaginal disc growth factor 2' (idgf2). Idgf2 has been previously shown to cause proliferation of fruit fly cells via an unknown pathway. For human kidney cells in culture, we have discovered that depletion of DIS3L2 results in enhanced proliferation, and that this involves a well known cellular pathway. We do not yet know the mRNA targets of DIS3L2 which activate this proliferation pathway in humans. These results are novel in that no other research group as yet has unravelled the cellular mechanisms linking DIS3L2 with cell proliferation.
The specific aims of this project are to understand the pathways and cellular mechanisms whereby Dis3L2 controls cell proliferation in Drosophila and in human kidney cells. We will use modern molecular and cell biological methods (such as CRISPR-Cas9 for gene editing) to dissect this proliferation pathway and identify key components. In fruit flies, we think that Dis3L2 directly targets idgf2 after it has been "tagged" for degradation by other cellular factors. We predict that Idgf2 then activates a specific cellular enhance cell proliferation. In humans, we predict that DIS3L2 targets another growth factor which in turn activates the same pathway to promote proliferation. We have the expertise, as well as the molecular and genetic tools to test these ideas. The knowledge gained during this project may facilitate treatments for cancer as well as help us to understand the ways that normal tissues grow and develop. This project will therefore provide valuable insights into a new way of regulating cell proliferation which can be used in the development of new therapeutics.
Technical Summary
Dis3L2 is a cytoplasmic 3'-5' exoribonuclease which is a member of the RNase II/RNB family conserved from bacteria to humans. Using Drosophila, we have shown that null mutations in dis3L2 result in substantial tissue overgrowth due to increased cellular proliferation. This proliferation effect seen in Drosophila tissue upon Dis3L2 depletion is similar to that seen in humans, where mutations in human DIS3L2 are associated with Perlman syndrome (a congenital overgrowth condition) and sporadic cases of Wilms' tumour. It has previously been shown in tissue culture cells that DIS3L2 can target non-coding RNAs such as snRNAs and snoRNAs but it is unclear how these targets might affect proliferation in-vivo.
Our recent work offers the first feasible explanation for the overgrowth observed in Dis3L2-deficient tissues. We show that Dis3L2 targets the imaginal disc growth factor idgf2 which is responsible for driving wing overgrowth in Drosophila. We also show that loss of DIS3L2 in human HEK-293T cells results in cell proliferation in a mechanism dependent upon the PI3-Kinase/AKT pathway. However, the intracellular pathway regulated by Idgf2 to control proliferation in Drosophila is unknown. In humans, the RNA targeted by DIS3L2 to regulate the PI3-Kinase/AKT pathway remains elusive. In both organisms, the mechanisms whereby Dis3L2 selectively regulates its target is also unknown.
The overall aim of this project is to dissect the molecular and cellular pathways regulated by Dis3L2 to control proliferation in Drosophila and in human cells. Our hypothesis is that Dis3L2 acts through the PI3-Kinase/AKT pathway to regulate proliferation in both organisms but targets different growth factors to control this pathway. Using a range of techniques we will test this hypothesis to unlock the molecular and cellular mechanisms involved. This work will provide valuable insights into a new method of gene regulation which can be used in the development of new therapeutics.
Our recent work offers the first feasible explanation for the overgrowth observed in Dis3L2-deficient tissues. We show that Dis3L2 targets the imaginal disc growth factor idgf2 which is responsible for driving wing overgrowth in Drosophila. We also show that loss of DIS3L2 in human HEK-293T cells results in cell proliferation in a mechanism dependent upon the PI3-Kinase/AKT pathway. However, the intracellular pathway regulated by Idgf2 to control proliferation in Drosophila is unknown. In humans, the RNA targeted by DIS3L2 to regulate the PI3-Kinase/AKT pathway remains elusive. In both organisms, the mechanisms whereby Dis3L2 selectively regulates its target is also unknown.
The overall aim of this project is to dissect the molecular and cellular pathways regulated by Dis3L2 to control proliferation in Drosophila and in human cells. Our hypothesis is that Dis3L2 acts through the PI3-Kinase/AKT pathway to regulate proliferation in both organisms but targets different growth factors to control this pathway. Using a range of techniques we will test this hypothesis to unlock the molecular and cellular mechanisms involved. This work will provide valuable insights into a new method of gene regulation which can be used in the development of new therapeutics.
Planned Impact
Who will benefit from this research?
The main beneficiaries of the proposed work comprise those in the Pharmaceutical industry, Clinicians, Biomedical Scientists and the General Public (including schoolchildren). Although this project is primarily "basic, blue-sky research" it nevertheless will lead to new insights important for therapeutics in the future.
How will they benefit from this research?
1. Pharmaceutical Industry and Biotechnology
Since the proposed project aims to understand a new pathway controlling proliferation, it is highly likely that we will find new "druggable" targets for cancer and to promote regeneration (e.g. liver regeneration). We will therefore aim to collaborate with the Sussex Drug Discovery Centre to find molecules which affect the activity of DIS3L2 or downstream targets. The proposed research is also of relevance to industrialists as it may provide a pathway to molecular therapeutics based on the modulation of RNA stability. The project will also be highly relevant to work on microRNA biomarkers because it will shed light on their functional relevance to proliferation plus enhance our expertise in methodologies (e.g poly-ribo-seq). Our previous BBSRC-funded research led to work on microRNAs/non-coding RNAs as biomarkers in myeloma, sepsis, melanoma and Motor Neurone Disease (ALS) resulting in 4 publications (plus 2 in prep) and 2 patents. We are therefore familiar with working with the Sussex Innovation Centre to market and patent microRNA biomarkers. We have previously been awarded a BBSRC "Sparking Impact" Award to market and patent microRNA biomarkers in melanoma.
2. Clinicians
Clinicians will benefit from the proposed research because the project will provide fundamental insights relevant to their research on human diseases. With the work taking place in a Medical School there is ample scope to engage clinicians and medical researchers to take advantage of the knowledge and expertise we have developed. Indeed, clinicians have already benefitted from our previous BBSRC-funded research, particularly in the area of microRNA biology and cancer. We are currently collaborating with 3 clinical research groups to explore the use of microRNAs as biomarkers in a variety of human diseases. The proposed project will allow cross-fertilization of ideas on medically related topics which will therefore contribute to our continued efforts to enhance the quality of life in the UK.
3. General Public and Schools
We think it is important to disseminate our research to a wider public because we are interested in fundamental problems that are ultimately relevant to human health. The main theme of the work, concerning gene regulation of RNAs involved in proliferation, will be both surprising and fascinating to the public, particularly as there are clinical implications. We will present our work at the Brighton Science Festival, as well as at Open Days and during outreach activities over the duration of the funding to children in local schools.
4. Capacity building for research staff
The proposal includes high level training for the Research Co-Investigator at top laboratories world-wide in order for him to become an Independent Researcher. The research skills he will learn will include CRISPR/Cas9 in human cells, biochemical techniques to detect RNA-binding proteins and in-vivo labeling of RNA. This training will also benefit his networking and communications skills. The usefulness of these skills is demonstrated by one of my previous post-docs who is now working in a biomarker spin-out company in North Carolina (USA). Another previous postdoc, who now has a permanent position as a Medical Statistician at BSMS, gained his bioinformatic skills by working as a BBSRC-funded postdoc in my lab. The Research Co-Investigator funded on the grant will be in a position to teach high-level techniques to PhD students including clinical undergraduate/PhD/MD students as well as NHS Biomedical Scientists.
The main beneficiaries of the proposed work comprise those in the Pharmaceutical industry, Clinicians, Biomedical Scientists and the General Public (including schoolchildren). Although this project is primarily "basic, blue-sky research" it nevertheless will lead to new insights important for therapeutics in the future.
How will they benefit from this research?
1. Pharmaceutical Industry and Biotechnology
Since the proposed project aims to understand a new pathway controlling proliferation, it is highly likely that we will find new "druggable" targets for cancer and to promote regeneration (e.g. liver regeneration). We will therefore aim to collaborate with the Sussex Drug Discovery Centre to find molecules which affect the activity of DIS3L2 or downstream targets. The proposed research is also of relevance to industrialists as it may provide a pathway to molecular therapeutics based on the modulation of RNA stability. The project will also be highly relevant to work on microRNA biomarkers because it will shed light on their functional relevance to proliferation plus enhance our expertise in methodologies (e.g poly-ribo-seq). Our previous BBSRC-funded research led to work on microRNAs/non-coding RNAs as biomarkers in myeloma, sepsis, melanoma and Motor Neurone Disease (ALS) resulting in 4 publications (plus 2 in prep) and 2 patents. We are therefore familiar with working with the Sussex Innovation Centre to market and patent microRNA biomarkers. We have previously been awarded a BBSRC "Sparking Impact" Award to market and patent microRNA biomarkers in melanoma.
2. Clinicians
Clinicians will benefit from the proposed research because the project will provide fundamental insights relevant to their research on human diseases. With the work taking place in a Medical School there is ample scope to engage clinicians and medical researchers to take advantage of the knowledge and expertise we have developed. Indeed, clinicians have already benefitted from our previous BBSRC-funded research, particularly in the area of microRNA biology and cancer. We are currently collaborating with 3 clinical research groups to explore the use of microRNAs as biomarkers in a variety of human diseases. The proposed project will allow cross-fertilization of ideas on medically related topics which will therefore contribute to our continued efforts to enhance the quality of life in the UK.
3. General Public and Schools
We think it is important to disseminate our research to a wider public because we are interested in fundamental problems that are ultimately relevant to human health. The main theme of the work, concerning gene regulation of RNAs involved in proliferation, will be both surprising and fascinating to the public, particularly as there are clinical implications. We will present our work at the Brighton Science Festival, as well as at Open Days and during outreach activities over the duration of the funding to children in local schools.
4. Capacity building for research staff
The proposal includes high level training for the Research Co-Investigator at top laboratories world-wide in order for him to become an Independent Researcher. The research skills he will learn will include CRISPR/Cas9 in human cells, biochemical techniques to detect RNA-binding proteins and in-vivo labeling of RNA. This training will also benefit his networking and communications skills. The usefulness of these skills is demonstrated by one of my previous post-docs who is now working in a biomarker spin-out company in North Carolina (USA). Another previous postdoc, who now has a permanent position as a Medical Statistician at BSMS, gained his bioinformatic skills by working as a BBSRC-funded postdoc in my lab. The Research Co-Investigator funded on the grant will be in a position to teach high-level techniques to PhD students including clinical undergraduate/PhD/MD students as well as NHS Biomedical Scientists.
Publications
Joilin G
(2022)
Profiling non-coding RNA expression in cerebrospinal fluid of amyotrophic lateral sclerosis patients.
in Annals of medicine
Negash M
(2024)
Evidence for immune activation in pathogenesis of the HLA class II associated disease, podoconiosis
in Nature Communications
Pashler AL
(2021)
Genome-wide analyses of XRN1-sensitive targets in osteosarcoma cells identify disease-relevant transcripts containing G-rich motifs.
in RNA (New York, N.Y.)
Pueyo JI
(2023)
Purriato is a conserved small open reading frame gene that interacts with the CASA pathway to regulate muscle homeostasis and epithelial tissue growth in Drosophila.
in Frontiers in cell and developmental biology
Samuels M
(2023)
The role of non-coding RNAs in extracellular vesicles in breast cancer and their diagnostic implications.
in Oncogene
Description | Biochemical Society Events grant |
Amount | £500 (GBP) |
Organisation | Biochemical Society |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 12/2021 |
End | 03/2022 |
Description | Determining the role of long non-coding RNA in the pathogenesis of high risk, gain(1q) positive, multiple myeloma |
Amount | £87,327 (GBP) |
Organisation | University of Sussex |
Department | Brighton and Sussex Medical School |
Sector | Academic/University |
Country | United Kingdom |
Start | 10/2023 |
End | 09/2026 |
Description | RNA Salon grant |
Amount | $3,000 (USD) |
Organisation | RNA Society |
Sector | Charity/Non Profit |
Country | United States |
Start | 10/2021 |
End | 09/2023 |
Description | Regulating RNA stability to increase protein production of cells under stress conditions |
Amount | £104,436 (GBP) |
Funding ID | 2457522 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 10/2020 |
End | 09/2024 |
Title | Antibody to Drosophila Dis3L2 |
Description | We have generated an excellent antibody to Drosophila Dis3L2. |
Type Of Material | Biological samples |
Year Produced | 2021 |
Provided To Others? | Yes |
Impact | Acknowledgement on Academic publications |
Title | data associated with "Genome-wide analyses of XRN1-sensitive targets in osteosarcoma cells identifies disease-relevant transcripts containing G-rich motifs. RNA 10:1265-1280" |
Description | RNA-seq data |
Type Of Material | Database/Collection of data |
Year Produced | 2021 |
Provided To Others? | Yes |
Impact | None as yet |
Description | Collaboration with Dr John Jones and Dr Ben Towler |
Organisation | University of Sussex |
Department | School of Life Sciences Sussex |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | John Jones is a clinician who is interested in identifying novel genes which are involved in the severity and progression of myeloma. Dr Ben Towler and I are contributing our expertise in ncRNAs to identify lncRNAs which might be involved in myeloma progression. |
Collaborator Contribution | John Jones is a clinician who can obtain samples of bone marrow and interpret NHS records. He has been awarded funding for a PhD studentship to support this study. |
Impact | None as yet. |
Start Year | 2022 |
Description | Collaboration with Dr Mel Flint and Dr Georgios Giamas |
Organisation | University of Brighton |
Department | Faculty of Science and Engineering |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | In this collaboration, my research team is providing expertise in the analysis of microRNAs within exosomes that might signal between ovarian cancer cells upon endocrine stress. |
Collaborator Contribution | Dr Mel Flint has expertise in gene regulation upon endocrine stress; Dr Georgios Giamas has expertise in exosome trafficking. |
Impact | Applied for grant funding which was unsuccessful. Intend to resubmit the grant elsewhere.. |
Start Year | 2017 |
Description | Collaboration with Dr Rohan Lewis and Dr Jane Cleal (University of Southampton) |
Organisation | University of Southampton |
Department | Southampton Medical School |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | My team is providing advice on the identification and analysis of RNA biomarkers secreted into the womb during pregnancy. |
Collaborator Contribution | The work is being carried out in Dr Lewis' lab by a BBSRC-DTP-funded PhD student. I am listed as Co-Supervisor of the student. |
Impact | No outputs as yet |
Start Year | 2020 |
Description | Collaboration with Dr Sandra Sacre and Dr Val Jenkins |
Organisation | University of Sussex |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We have provided expertise in the detection and analyses of non-coding RNAs in serum in patients with "chemo-brain". |
Collaborator Contribution | Dr Sacre has organised the permissions for the patient samples. Dr Val Jenkins has carried out qualitative "Quality of Life" tests. |
Impact | No outputs as yet. The experiments were delayed because of the COVID-19 situation. |
Start Year | 2018 |
Description | Collaboration with Prof Majid Hafezparast, Prof Nigel Leigh and Prof Martin Turner |
Organisation | University of Sussex |
Department | School of Life Sciences Sussex |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | This is a longstanding and very successful collaboration where we are searching for non-coding RNA biomarkers in Motor Neurone Disease (ALS) and other neurodegenerative diseases. Myself and my research team have provided expertise on the RNA Biology aspects of the project and contributed towards publications and grant applications. |
Collaborator Contribution | Prof Majid Hafezparast is a neuroscientist with expertise in nsurodegenerative diseases. His lab is leading our collaborative projects. Prof Nigel Leigh is a clinical neurologist who provides the clinical expertise and sources human samples. Prof Martin Turner, at the University of Oxford, has provided high quality serum and cerebrospinal fluid samples. |
Impact | 4 publications, 4 conference presentations, 2 grants from the Motor Neurone Disease Association to fund a postdoc and consumables, 1 grant from the My name i5 Doddie Foundation, 1 grant from the Motor Neurone Disease Association to fund a studentship, 1 internal pump-priming grant. |
Start Year | 2013 |
Description | Collaboration with Prof Mel Newport |
Organisation | University of Sussex |
Department | Brighton and Sussex Medical School |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Prof Mel Newport wishes to collaborate on a project to identify microRNA biomarkers that might be useful in prognosis or the understanding of podoconiosis. This is a disfiguring disease which is prevalent in African countries such as Ethiopia and has a genetic component. Her group already have serum samples from patients and her postdoc is able to do the work. Therefore Dr Ben Towler and myself will be able to advise her on techniques. |
Collaborator Contribution | Our partner will be able to provide patient serum samples and also a postdoc plus consumables to do the work. |
Impact | None as yet |
Start Year | 2022 |
Description | Collaboration with Prof Mel Newport |
Organisation | University of Sussex |
Department | Brighton and Sussex Medical School |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Prof Mel Newport wishes to collaborate on a project to identify microRNA biomarkers that might be useful in prognosis or the understanding of podoconiosis. This is a disfiguring disease which is prevalent in African countries such as Ethiopia and has a genetic component. Her group already have serum samples from patients and her postdoc is able to do the work. Therefore Dr Ben Towler and myself will be able to advise her on techniques. |
Collaborator Contribution | Our partner will be able to provide patient serum samples and also a postdoc plus consumables to do the work. |
Impact | None as yet |
Start Year | 2022 |
Description | Collaboration with Prof Neil Harrison and Dr Jessica Eccles. |
Organisation | Cardiff University |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | My team have been advising Marisa Amato, who is a PhD student working with Jessica Eccles and Neil Harrison on inflammation and Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). She has been using RNA-seq to analyse gene expression in patient blood to understand this complex syndrome. My team have helped her prepare the RNA libraries and analyse results. |
Collaborator Contribution | The PhD student is funded by a grant to Neil Harrison and has used funding on this grant to pay for all required consumables. |
Impact | A student is is continuing to analyse the results so there are no outputs as yet. |
Start Year | 2020 |
Description | Collaboration with Prof Steve West, University of Exeter |
Organisation | University of Exeter |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | This collaboration, using a technique developed in Prof West's lab, will lead to publications where relevant members of his team will be included as co-authors. |
Collaborator Contribution | Steve West's group has considerable expertise in constructing cell lines carrying proteins tagged with an auxin-inducible degron tag and have been successful in tagging similar proteins to DIS3L2. Prof West is supplying experimental advice as well as relevant plasmids. |
Impact | The work has recently started so there are no outputs, as yet. |
Start Year | 2020 |
Description | Collaboration with Professor Mark Smales, University of Kent. |
Organisation | University of Kent |
Department | School of Biosciences |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | A BBSRC-DTP-funded PhD student is working in my lab on a project to enhance to production of bioactive peptides. |
Collaborator Contribution | Prof Smales is advising the PhD student on techniques and is her second Supervisor. |
Impact | No outputs as yet |
Start Year | 2020 |
Title | Circulating RNA biomarkers for diagnosis/prognosis of Chronic Fatigue Syndrome |
Description | Together with Prof Jessica Eccles and Prof Neil Harrison, we are advising a PhD student on the identification of RNA biomarkers from the prognosis/diagnosis of Chronic Fatigue Syndrome. |
Type | Diagnostic Tool - Non-Imaging |
Current Stage Of Development | Initial development |
Year Development Stage Completed | 2023 |
Development Status | Under active development/distribution |
Impact | This is the first time that promising RNA biomarkers have been detected for this disease. |
Title | Circulating RNA biomarkers for diagnosis/prognosis of motor neurone disease |
Description | We have identified circulating RNA biomarkers for use in diagnosis/prognosis of motor neurone disease (also known as ALS). These biomarkers show promise not only in the diagnosis of this disease but also in distinguishing fast-progressing from slow-progressing forms of the disease. This is in collaboration with Dr Majid Hafezparast (Life Sciences, University of Sussex), Professor Nigel Leigh (BSMS) and Professor Martin Turner (University of Oxford). The project is at present funded by the Motor Neurone Disease Association. |
Type | Diagnostic Tool - Non-Imaging |
Current Stage Of Development | Initial development |
Year Development Stage Completed | 2020 |
Development Status | Actively seeking support |
Impact | Recently, we have started a collaboration with a Commercial Company to improve techniques for identification of these biomarkers in serum from patients. |
Title | Circulating RNA biomarkers for prognosis of chemo-brain in breast cancer. |
Description | A BSMS colleague and I have identified circulating RNA biomarkers which may identify breast cancer patients who greatly suffer from "chemo-brain" during treatment for breast cancer. These patients suffer anxiety and forgetfulness as a result of the chemotherapy they are given for their breast cancer. Identification of patients who suffer more than others may inform treatment in future. |
Type | Diagnostic Tool - Non-Imaging |
Current Stage Of Development | Initial development |
Year Development Stage Completed | 2020 |
Development Status | Under active development/distribution |
Impact | Note that this product is relevant to women and not "man" !! No impacts as yet. |
Description | Moderna roundtable on the Future of mRNA at Chatham House 14th December 2022. |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | I was one of four lab-based scientists invited to the Roundtable on the Future of mRNA at Chatham House 14th December 2022 led by Moderna. The event was also attended by UKHSA plus academic social scientists and experts on patent law. |
Year(s) Of Engagement Activity | 2022 |
Description | RNA mini-symposium |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Postgraduate students |
Results and Impact | Ben Towler (BSMS) and Greig Joilin (Life Sciences) organised a very successful RNA mini-symposium on Tuesday 1 December. The event, which was attended by more than 30 PhD students, postdocs and faculty from across BSMS and Life Sciences at the University of Sussex, was run as part of a 'RNA Salon' sponsored by an RNA Society grant (held by Prof Sarah Newbury, Ben Towler and Greig Joilin) and Lexogen. Future events, whether virtually, in-person or a combination, are currently in the works for the new year to not only help increase collaboration across BSMS and Life Sciences, but also to provide opportunities for early career researchers to share their work. |
Year(s) Of Engagement Activity | 2020 |
Description | South Coast RNA Network |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Type Of Presentation | workshop facilitator |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | I set up the South Coast RNA Network meetings, which involve groups working on RNA Biology from Universities on (or near) the South Coast of England together with representatives from Industry. The first meeting, in November 2009, was organised by myself, Professor Simon Morley and the University of Sussex Business and Enterprize Office. The half-day meeting, which was free to Academic delegates, was extremely successful and has been followed up by a second meeting in November 2010 at the University of Surrey, a 3rd meeting in November 2011 at the University of Portsmouth and subsequent meetings at the University of Kent and the University of Sussex. In 2021, the event took place at the University of Sussex and was organised by myself and Ben Towler. It was the first face-to-face meeting after lockdown. The co-organisers for these meetings are post-docs and PhD students, which gave them an opportunity to learn the skills of meeting organisation. The next meeting is planned in November, 2023, hosted by the University of Portsmouth. This series of meetings has give rise to a number of research collaborations and successful grant applications. It has also given researchers the opportunity to interact with potential Industrial partners. |
Year(s) Of Engagement Activity | 2009,2010,2011,2012,2013,2017,2022 |
Description | Sussex RNA Biology Research Group network |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Postgraduate students |
Results and Impact | Founded the Sussex RNA Biology Network. Members of the group share common interests in the way that RNA molecules can regulate the expression of genes important for cellular processes such as proliferation and migration, as well as human diseases. The group works on interlinked but complementary projects using a diverse range of organisms and techniques with the ultimate aim of understanding the ways that RNA-based regulation can be manipulated to alleviate human disease. |
Year(s) Of Engagement Activity | 2019,2020,2021,2022 |
URL | https://www.bsms.ac.uk/research/clinical-and-experimental-medicine/rna-biology-research-group/index.... |